Welcome to our dedicated page for Zura Bio SEC filings (Ticker: ZURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zura Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zura Bio's regulatory disclosures and financial reporting.
Zura Bio Ltd director Parvinder Thiara reported receiving a share option award covering 38,823 Class A Ordinary Shares. The option, with a conversion or exercise price of $6.36 per share, was granted on January 23, 2026 and is held directly.
The option vests in twelve substantially equal monthly installments over a one-year period starting January 23, 2026. Any remaining unvested portion will vest on the day immediately preceding the next annual meeting of shareholders following the grant date, subject to Thiara’s continued service on each vesting date.
Zura Bio Ltd director Parvinder Thiara reported initial derivative holdings in the company. This Form 3 shows two stock option positions over Class A ordinary shares.
The director holds a share option for 48,149 Class A ordinary shares at an exercise price of $3.98, expiring on 01/24/2034, which is described as immediately exercisable. A second share option covers 117,000 Class A ordinary shares at an exercise price of $2.76, expiring on 12/09/2034, also reported as immediately exercisable.
Athanor Capital and UGS Capital LLC filed a Schedule 13D reporting beneficial ownership of 11,581,402 Class A Ordinary Shares of Zura Bio Limited, representing about 15.7% of the company’s outstanding Class A shares, based on 73,680,710 shares.
On December 29, 2025, Zura Bio issued Athanor Capital 8,657,402 Class A shares under a letter agreement, with no cash paid; the shares were issued in exchange for terminating prior agreements and transferring certain contractual rights. The investors state the stake is held for investment purposes, without a present intent to change or influence control, though they may review the position over time. Parvinder Thiara, associated with both entities, was reappointed to Zura Bio’s board effective January 23, 2026.
Zura Bio Limited announced a leadership transition. Robert Lisicki resigned as Chief Executive Officer, principal executive officer and director, effective January 21, 2026, after previously taking medical leave. Under a separation agreement, he will remain a non-executive employee through March 31, 2026 with transition pay of $72,000 on an annualized basis, a lump-sum severance equal to 12 months of base salary reduced by that transition pay, COBRA premiums for up to nine months, an extended 12‑month post-termination option exercise window, and accelerated vesting for 25% of the stock options granted to him on February 27, 2025.
The Board appointed director Dr. Sandeep Kulkarni as Chief Executive Officer and principal executive officer, with an annual base salary of $655,000 and a target bonus equal to 55% of base salary, and equity awards under the 2023 Equity Incentive Plan. Kim Davis stepped down from interim CEO duties and continues as Chief Operating Officer, Chief Legal Officer and Corporate Secretary. The Board also appointed Parvinder Thiara as a director, with a prorated $40,000 annual cash retainer and stock option grants tied to service under the Non-Employee Director Compensation Policy.
Zura Bio Ltd reported that Chief Executive Officer and director Sandeep Chidambar Kulkarni received an employee stock option grant on January 21, 2026. The option covers 2,934,107 Class A Ordinary Shares at an exercise price of $6.32 per share and expires on January 21, 2036.
According to the vesting terms, one fourth of the options will vest on January 21, 2027, and the remaining options will vest in equal quarterly installments, with one twelfth of the remaining shares vesting each quarter. Vesting is conditioned on the CEO’s continuous service with the company.
Zura Bio Limited furnished a new corporate presentation and issued a press release tied to its business outlook. The presentation, dated January 12, 2026, may be used at conferences and investor meetings and is available as Exhibit 99.1 and through the company’s investor website.
The press release, filed as Exhibit 99.2, discusses corporate and clinical trial updates and the company’s outlook for 2026, including its cash runway and expected topline data timelines for two ongoing Phase 2 studies of tibulizumab in hidradenitis suppurativa and systemic sclerosis. Both exhibits are referenced in this current report.
Zura Bio Limited reported that Arnout Ploos van Amstel resigned from its Board of Directors and from the Board’s Nominating and Governance Committee effective December 11, 2025. The company states that his decision is not due to any disagreement with its operations, policies or practices.
The disclosure centers on this board-level governance change. Zura Bio is organized in the Cayman Islands, is an emerging growth company, and its Class A ordinary shares trade on the Nasdaq Stock Market under the symbol ZURA.
Zura Bio Limited reported its Q3 2025 results. Cash and cash equivalents were $139.0 million as of September 30, 2025, compared with $176.5 million at year-end 2024. The company recorded a net loss of $18.0 million for the quarter and $51.5 million for the nine months, reflecting ongoing investment in clinical programs.
Quarterly operating expenses were $19.5 million, with research and development at $11.9 million and general and administrative at $7.6 million. Net cash used in operating activities was $42.5 million for the nine months. Management states it should have sufficient liquidity to fund operations over the next twelve months.
The pipeline centers on Phase 2 development of tibulizumab (ZB-106), a dual IL‑17A/BAFF bispecific antibody. During 2025, the company sold 3,000,000 shares under its ATM at $1.75 for $5.1 million in net proceeds. Class A Ordinary Shares outstanding were 65,018,058 as of September 30, 2025, and 65,023,308 as of November 10, 2025.
Zura Bio Limited furnished a press release announcing its third quarter 2025 financial results. The release was provided as Exhibit 99.1 to a Form 8-K dated November 13, 2025. Under Item 2.02, the information (including Exhibit 99.1) is deemed furnished, not filed, and is not incorporated by reference except as specifically stated.
Zura Bio Limited reported a leadership change triggered by a medical leave. On October 8, 2025, Chief Executive Officer and Board member Robert Lisicki informed the company that he is taking a medical leave of absence effective October 10, 2025.
The Board appointed Kim Davis, currently Chief Operating Officer, Chief Legal Officer and Corporate Secretary, to serve as interim Chief Executive Officer and interim principal executive officer starting October 10, 2025, while she continues in her existing roles. The company notes that there are no special arrangements behind her appointment, no related-party transactions requiring disclosure, and no family relationships between Davis and any directors or executive officers.